# Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

> **NCT04032964** · PHASE1 · UNKNOWN · sponsor: **Philogen S.p.A.** · enrollment: 2 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** L19TNF
- **DRUG:** DOXORUBICIN

## Key facts

- **NCT ID:** NCT04032964
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-05
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2024-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04032964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04032964, "Dose Finding Study of L19TNF and Doxorubicin in Patients With STS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04032964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*